Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine

Biologicals

Volumn 24, Issue 3, 1996, Pages 235-242

  Vidor, Emmanuel ^a,f   Xueref, Colette ^a   Blondeau, Christine ^a   Bajard, Abel ^a   Francon, Alain ^a   Goudeau, Alain ^b   Peyron, Francois ^c   Brasseur, Philippe ^d   Zuckerman, Arie ^e  

^a Pasteur Merieux Serums et Vaccins   (France)

^b CHU BRETONNEAU   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f Pasteur Merieux Connaught   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY; MALE; META ANALYSIS; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEROCONVERSION; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0030239421     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1996.0032     Document Type: Article

References (46)

1. 1. Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br Med Bull 1990; 46: 303-318.
2. 2. Lemon SM. Type A viral hepatitis: new developments in an old disease. N Engl J Med 1985; 313: 1059-1067.
3. 3. Melnick JL. Properties and classification of hepatitis A virus. Vaccine 1992;10: S24-S26.
4. 4. Hollinger FB, Ticehurst JR. Hepatitis A virus. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press Ltd, 1990, 631-667.
5. 5. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993; 18: S51-S55.
6. 6. Armstrong ME, Giesa PA, Davide JP et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA (TM) from the live attenuated virus strain CR326F. J Hepatol 1993; 18: S20-S26.
7. 7. Flehmig B, Haage A, Heinricy U et al. Studies with an inactivated hepatitis A vaccine. In: Zuckerman AJ, ed., Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc, 1988, 100-105.
8. 8. André FE, Hondt d' E, Delem AD et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine-rationale and summary of findings. Vaccine 1992; 10: S160-S168.
9. 9. Clemens R, Safary A, Hepburn A et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171 ( Suppl. 1): S44-S49.
10. 10. Pellegrini V, Fineschi N, Matteucci G et al. Preparation and immunogenicity of an inactivated hepatitis A vaccine. Vaccine 1993; 11: 383-387.
11. 11. Glück R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992; 10: 915-919.
12. 12. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995; 13: 891-893.
13. 13. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992; 14:580-586.
14. 14. Behrens RH, Doherty JF. Severe hepatitis A despite passive immunisation. Lancet 1993; 341: 972.
15. 15. Gerety RJ, Smallwood LA, Finlayson JS et al. Standardization of the antibody to hepatitis A virus (anti-HAV ) content of immunoglobulin. Develop Biol Standard 1983; 54: 411-416.
16. 16. Safford S, Needleman SB, Decker RH. Radioimmunoassay for detection of antibody to hepatitis A virus: results of clinical evaluation. Am J Clin Pathol 1980; 74: 25-31.
17. 17. Stapleton JT. Passive immunization against hepatitis A. Vaccine 1992; 10: S45-S47.
18. 18. Kendall BJ, Cooksley WG. Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts. Drugs 1991; 41: 883-888.
19. 19. Zaaijer HL, Leentvaarkuijpers A, Rotman H et al. Hepatitis A antibody titres after infection and immunization-implications for passive and active immunization. J Med Virol 1993; 40: 22-27.
20. 20. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. J Am Med Assoc 1994; 271: 1328-1334.
21. 21. Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New Engl J Med 1992; 327:453-457.
22. 22. Miller WJ, Clark W, Hurni WM et al. Sensitive assays for hepatitis A antibodies. J Med Virol 1993; 41: 201-204.
23. 23. Garin D, Vidor E, Wallon M et al. Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 1995; 13: 220-224.
24. 24. Goilav C, Zuckerman JN, Lafrenz M et al. Immunogencity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 1995; 46: 287-292.
25. 25. Flehmig B, Vallbracht A, Wurster G. Hepatitis A in cell culture. 3.Propagation of hepatitis virus in human embryo kidney cells and human embryo fibroblast strains. Med Microbiol Immunol 1981; 170: 83-89.
26. 26. Heinricy U, Hentscel J, Pfisterer M, Flehmig B. Hepatitis A: biophysical characterization and electron microscopy of infectious hepatitis A virus. Zent Bakteriol Hyg 1983; A257: 139-142.
27. 27. Heinricy U, Stierhof YD, Pfisterer M et al. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol 1987; 68: 2487-2493.
28. 28. Graff J, Normann A, Feinstone SM et al. Nucleotide sequence of wild-type hepatitis A virus GBM in comparison to two cell culture-adapted variants. J Virol 1994; 68: 548-554.
29. 29. Graff J, Kasang C, Normann A et al. Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation. Virology 1994; 204: 60-68.
30. 30. Frosner GG, Overby LR, Flehmig B et al. Serological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol 1977; 1: 163-173.
31. 31. Flehmig B, Mauler RF, Noll G et al. Progress in the development of an attenuated, live hepatitis A vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. Alan R. Liss, Inc, 1988, 87-90.
32. 32. Flehmig B, Haage A, Pfisterer M. Immunogenicity of a hepatitis A virus vaccine. J Med Virol 1987; 22: 7-16.
33. 33. Flehmig B, Heinricy U, Pfisterer M. Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet 1989; 1: 1039-1041.
34. 34 Flehmig B, Heinricy U, Pfisterer M. Simultaneous vaccination for hepatitis A and B. J Infect Dis 1990; 161: 865-868.
35. 35. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984; 6: S540-S544.
36. 36. Flehmig B, Zahn J, Vallbracht A. Levels of neutralizing and binding antibodies to hepatitis A virus after onset of icterus: a comparison. J Infect Dis 1984; 150: 461.
37. 37. Krah DL, Amin RD, Nalin DR, Provost PJ. A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. J Infect Dis 1991; 163: 634-637.
38. 38. Lemon SM. Hepatitis A virus: current concepts of the molecular virology, immunobiology, and approaches to vaccine development. Rev Med Virol 1992; 2: 73-87.
39. 39. Shouval D, Ashur Y, Adler R et al. Single and booster dose responses to an inactivated Hepatitis A virus vaccine - comparison with immune serum globulin prophylaxis. Vaccine 1993; 11: S9-S14.
40. 40. Berger R, Just M, Althaus B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: The results are highly dependent on the antibody test system used. J Virol Methods 1993; 43: 287-297.
41. 41. Delem AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals 1992; 20: 289-291.
42. 42. Shouval D, Ashur Y, Adler R et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine-effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol 1993; 18: S32-S37.
43. 43. Goubau P, Vangerven V, Safary A et al. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 1992; 10: S114-S118.
44. 44. Ellerbeck EF, Lewis JA, Nalin DR et al. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine 1992; 10: 668-672.
45. 45. Tilzey AJ, Palmer SJ, Barrow S et al. Effect of Hepatitis A vaccination schedules on immune response. Vaccine 1992; 10: S121-S123.
46. 46. Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis-A virus. Vaccine 1992; 10: S40-S44.